Unilab unit expands healthcare product manufacturing

Published May 17, 2022, 3:01 PM

by Bernie Cahiles-Magkilat

Amherst Parenterals Inc., a subsidiary of the country’s largest pharmaceutical company Unilab Inc., is investing P291.212 million to expand its healthcare products manufacturing operation in Laguna.

The Board of Investments (BOI), which approved the project registration in September 2021, said Amherst inaugurated its new Sterile Liquid Production Line last month, an expansion of its existing manufacturing facility at Barangay Don Jose, Sta. Rosa, Laguna.

According to BOI, Amherst’s newly-constructed production line will be utilized in the manufacturing of sterile liquid solutions for nebulization (respiratory therapeutic products) as part of the company’s commitment to provide Filipinos with ready access to quality and affordable health care products.

Amherst is a toll manufacturer of respiratory therapy nebules including but not limited to Salbutamol and Salbutamol + Ipratropium.

Unilab, Inc. President Sebastian F. Baquiran cited the BOI for assisting them in coordinating with relevant various government agencies in the facilitating their permits and licenses.

“The government is very much appreciative of the company’s efforts and commitment to provide our countrymen with ready access to quality and affordable healthcare. Truly, this business decision of the company is very significant as the country continues to recover from the COVID-19 pandemic,” said BOI Executive Director Bobby Fondevilla in his key message at the Amherst manufacturing facility’s inauguration.

In his remarks, Executive Director Fondevilla underscored the crucial role that the pharmaceutical industry significantly plays in the Philippine economy.

The BOI, as the country’s lead Investment Promotion Agency, has been at the forefront of harnessing the manufacturing capacity of the local industry players as the country continues to recover from the pandemic.

Particularly, the BOI led the repurposing project for Personal Protective Equipment (PPEs), disinfectants, and ventilators; and industrial coordination to ensure that oxygen is available across all hospitals in the country during the Delta surge.

Previously, the BOI also approved the application for registration of Lloyd Laboratories, Inc. as domestic producer of Molnupiravir, an oral therapy for COVID-19 patients. The said project can produce an annual capacity of one million 400 mg capsules of Molnupiravir.